Alfresa Q1 Net Profit Halves as Wafer-Thin Wholesale Margin Thins Further

Revenue grows, every profit line falls

Alfresa Holdings Corporation (TSE: 2784), one of Japan's largest pharmaceutical wholesalers, reported consolidated first-quarter results for the three months to June 30, 2026 under Japanese GAAP on August 5, 2026. Revenue rose 4.1% to ¥788,960 million from ¥758,118 million, but operating profit fell 19.6% to ¥5,596 million, ordinary profit 20.5% to ¥6,088 million, and net profit attributable to owners of the parent 50.5% to ¥2,476 million. Earnings per share were ¥13.85 against ¥27.53.

The shape of that result — volume up, profit down — is the standing condition of Japanese drug distribution. The group turns over roughly ¥789 billion of goods in a quarter and keeps ¥5.6 billion of operating profit on it, a margin of 0.71%, down from 0.92% a year earlier. A margin measured in tenths of a percentage point means a small movement in purchase or delivery cost is a large movement in profit: here, ¥30.8 billion of extra revenue came with ¥1.4 billion less operating profit.

Net profit fell twice as fast as operating profit. Part of that is arithmetic below the operating line, and part is the share count: Alfresa bought back ¥14,999 million of its own stock in May 2026, lifting treasury shares to 15,886,528 from 9,582,018 and cutting the weighted average share count 1.7% to 178,807,346. The buyback supports EPS, but it cannot offset a halving of net profit — per-share earnings still fell 49.7%.

The segments: only the core holds its ground

Four reportable segments, and the profit picture divides cleanly. Ethical pharmaceutical wholesaling, the core, produced revenue of ¥709,803 million, up 4.6% (including ¥5,879 million of intersegment sales), and segment profit of ¥6,622 million, down 0.2% — essentially flat, and more than the group as a whole earned. Self-medication wholesaling turned over ¥66,171 million, down 1.1%, and its profit fell 40.4% to ¥537 million as higher logistics costs outran cost control.

The other two lost money and lost more of it than a year ago. Manufacturing had revenue of ¥11,957 million, down 5.3%, and an operating loss of ¥618 million against a ¥60 million loss. Dispensing pharmacies had revenue of ¥9,436 million, up 3.6%, and a loss of ¥498 million against ¥440 million, hit by drug-pricing revision, higher purchase costs and rising personnel expense. Together the two loss-makers cost ¥1,116 million, up from ¥500 million — which is most of the group's ¥1,368 million operating-profit decline.

Buyback, an acquisition and a regenerative-medicine stake

Alfresa is spending against a strategy rather than simply defending margin. The May buyback of ¥14,999 million was framed as a flexible capital-policy step to raise capital efficiency and shareholder returns. In the same month the group signed a share transfer agreement to acquire Nagashima Medical Instruments, a maker of medical devices for otorhinolaryngology and head-and-neck surgery, from Nagashima Holdings — a purchase intended to strengthen the group's device manufacturing and development and widen its own-product line-up in what it calls medical goods, one of its designated growth areas.

In June the group signed a further capital and business alliance with ReeNT, a research-driven venture out of the Jikei University School of Medicine, and made an additional investment in it. The stated aim is to bring ReeNT's autologous nasal mucosal epithelial cell sheets into practical use in Japan, with Alfresa supplying the contract-research, manufacturing and distribution functions that make up what it calls a regenerative-medicine total supply chain service.

All of this sits inside the "25-27 Medium-Term Management Plan, Vision2032 Stage2", whose five stated priorities are exercising group strength to expand the total supply chain service, strategic investment in growth and new businesses, further competitive strengthening of the base business, thorough cost control, and sustainability management.

Guidance unchanged, and it already implies a halving

Full-year guidance is unchanged: revenue of ¥3,144,000 million, up 1.3%; operating profit of ¥33,900 million, down 6.3%; ordinary profit of ¥36,600 million, down 5.3%; and net profit of ¥20,800 million, down 50.2%, for EPS of ¥116.47. First-half guidance is revenue of ¥1,542,000 million, up 0.8%, operating profit of ¥13,300 million, down 17.9%, ordinary profit of ¥14,500 million, down 17.1%, and net profit of ¥7,900 million, down 31.4%.

The mismatch inside that guidance is worth naming: ordinary profit is guided down 5.3% while net profit is guided down 50.2%. A gap that wide between the two lines does not come from trading — it says the prior year carried gains below the ordinary line that are not expected to repeat. On the quarter, the group has delivered 42.1% of half-year operating profit and 31.3% of half-year net profit, so the first half as guided requires a stronger second quarter than the first.

Total assets were ¥1,509,704 million at June 30, barely changed from ¥1,507,016 million. Net assets fell to ¥486,328 million from ¥507,903 million and equity to ¥485,635 million from ¥507,357 million — a ¥21.7 billion reduction against ¥2.5 billion of quarterly profit, which is the buyback plus the year-end dividend leaving the balance sheet. The equity ratio fell to 32.2% from 33.7%. The dividend forecast is unchanged at ¥35.00 interim and ¥36.00 final, ¥71.00 for the year, against ¥34.00 and ¥34.00 for ¥68.00 in FY3/2026 — a 4.4% increase declared against a year in which net profit is guided to halve.

JapanStockPulse provides informational content only and does not constitute investment advice. Figures are taken from the company's published earnings short report and may be subject to subsequent revision.